

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:52:19 ON 03 MAY 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.52

2.52

FILE 'REGISTRY' ENTERED AT 15:59:20 ON 03 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAY 2003 HIGHEST RN 509953-09-7

DICTIONARY FILE UPDATES: 2 MAY 2003 HIGHEST RN 509953-09-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STN Note 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 10082521.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 CO2H, COOH, COSH, CHO, C(O) CH3

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss ful

SEARCH FAILED DUE TO A STRUCTURE QUERY ERROR

The structure query could not be searched. Please review and revise your structure query, especially checking the variable definitions and attachments. In rare instances the failure may be due to a system problem. Please contact your local STN Help Desk if you need assistance.

=> s l1 full

FULL SEARCH INITIATED 16:00:47 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 57753 TO ITERATE

100.0% PROCESSED 57753 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.02

L2 0 SEA SSS FUL L1

---

=> s l1 sss

SAMPLE SEARCH INITIATED 16:00:55 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2986 TO ITERATE

33.5% PROCESSED 1000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 56444 TO 62996

PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS SAM L1

=> s l1

SAMPLE SEARCH INITIATED 16:02:06 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2986 TO ITERATE

33.5% PROCESSED 1000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 56444 TO 62996

PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L1

=> s l1 sss ful l1

COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID

The query entered contains both search terms created by structure-building or screen commands and text search terms. L#s created via the STRUCTURE or SCREEN commands must be searched in the structures files separately from text terms or profiles. The L# answer sets from structure searches can be used in crossover searches and can be combined with text terms.

=> s l1 sss ful

FULL SEARCH INITIATED 16:05:29 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 57753 TO ITERATE

100.0% PROCESSED 57753 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.02

L5 0 SEA SSS FUL L1

=> s l1

SAMPLE SEARCH INITIATED 16:05:39 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 2986 TO ITERATE

33.5% PROCESSED 1000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 56444 TO 62996  
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L1

=> file caplus, uspatfull, biosis, medline, cancerlit, drugu

<del>COST IN U.S. DOLLARS</del>	<del>SINCE FILE</del>	<del>TOTAL</del>
	ENTRY	SESSION
FULL ESTIMATED COST	300.30	302.82

FILE 'CAPLUS' ENTERED AT 16:06:42 ON 03 MAY 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:06:42 ON 03 MAY 2003  
CA. INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:06:42 ON 03 MAY 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 16:06:42 ON 03 MAY 2003

FILE 'CANCERLIT' ENTERED AT 16:06:42 ON 03 MAY 2003

FILE 'DRUGU' ENTERED AT 16:06:42 ON 03 MAY 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

=>

=> s isocoumarin#####  
L7 1917 ISOCOUMARIN#####

=> s glucocorticoid####  
L8 133145 GLUCOCORTICOID####

=> s dexamethason### or prednison###  
L9 227511 DEXAMETHASON### OR PREDNISON###

=> s l7 and l8  
L10 26 L7 AND L8

=> s l7 and l9  
L11 17 L7 AND L9

=> s l10 or l11  
L12 28 L10 OR L11

=> s l7 and cancer####  
L13 143 L7 AND CANCER####

=> s l13 and l9

L14 17 L13 AND L9

=> s l13 and l8

L15 25 L13 AND L8

=> s l14 or l15

L16 27 L14 OR L15

=> s vincristin##

L17 86336 VINCRISTIN##

=> s doxorubicin##

L18 117909 DOXORUBICIN##

=> s cisplatin

L19 128154 CISPLATIN

=> s cyclophosphamid##

L20 156136 CYCLOPHOSPHAMID##

=> s l20 or l19 or l18 ro l17

MISSING OPERATOR L18 RO

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l20 or l19 or l18 or l17

L21 360550 L20 OR L19 OR L18 OR L17

=> s l21 and l7

L22 15 L21 AND L7

=> dup remove l16

PROCESSING COMPLETED FOR L16

L23 26 DUP REMOVE L16 (1 DUPLICATE REMOVED)

=> d l23 1-26 bib,ab

L23 ANSWER 1 OF 26 USPATFULL

AN 2003:112921 USPATFULL

TI Method for the identification of active site protease inactivators

IN Baig, Salman, Athens, GA, UNITED STATES

PA The University of Georgia Research Foundation, Inc. (U.S. corporation)

PI US 2003077653 A1 20030424

AI US 2001-839428 A1 20010420 (9)

PRAI US 2000-198685P 20000420 (60)

US 2000-235123P 20000925 (60)

DT Utility

FS APPLICATION

LREP MUETING, RAASCH & GEBHARDT, P.A., P.O. BOX 581415, MINNEAPOLIS, MN, 55458

CLMN Number of Claims: 26

ECL Exemplary Claim: 1

DRWN 15 Drawing Page(s)

LN.CNT 5189

AB A method for identifying active site inhibitors of a target protease. Kinetic assays are employed to identify peptide substrates that tightly bind to the active site of the target protease but are not easily cleaved. These noncleavable but tightly binding substrates are structurally modified to yield inhibitory compounds that, additionally, exhibit apparent specificity for a transition state or ground state configuration of the protease.

L23 ANSWER 2 OF 26 USPATFULL

AN 2003:37557 USPATFULL

TI Methods of screening compounds for bioactivity in organized tissue  
IN Vandenburg, Herman H., Providence, RI, UNITED STATES  
Valentini, Robert F., Cranston, RI, UNITED STATES  
PI US 2003027202 A1 20030206  
AI US 2002-241618 A1 20020911 (10)  
RLI Continuation of Ser. No. US 1999-252324, filed on 18 Feb 1999, ABANDONED  
PRAI US 1998-75054P 19980218 (60)  
US 1998-86370P 19980522 (60)  
DT Utility  
FS APPLICATION  
LREP PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE,  
BOSTON, MA, 02199  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1414

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a method of screening a compound for bioactivity, comprising contacting a candidate bioactive compound with an organized tissue, and measuring in at least a cell of the organized tissue a biological parameter that is associated with bioactivity, wherein a change in the biological parameter that occurs as a result of the contacting step is indicative of bioactivity of the candidate compound.

L23 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2003/ACS DUPLICATE 1  
AN 2002:850322 CAPLUS  
DN 137:333136  
TI Tumor chemopotentialiation using isocoumarin derivatives  
IN Agata, Naoki; Kharbada, Surrender  
PA USA  
SO U.S. Pat. Appl. Publ., 30 pp., Cont. -in-part of U. S. Ser. No. 794,417.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002165210	A1	20021107	US 2002-82521	20020223
	US 2002019366	A1	20020214	US 2001-794417	20010227
PRAI	US 2000-186071P	P	20000229		
	US 2001-794417	A2	20010227		

AB A method for enhancing the efficacy of chemotherapy in the treatment of cancer in animals, particularly humans, is provided wherein isocoumarin derivs. that exhibit unique chemopotentialiation properties are employed in a combination treatment with chemotherapy. NM-3 [2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid] showed antiangiogenic activity and enhanced **dexamethasone** -induced apoptosis in human multiple myeloma cells.

L23 ANSWER 4 OF 26 USPATFULL  
AN 2002:198527 USPATFULL  
TI METHODS OF SCREENING COMPOUNDS FOR BIOACTIVITY IN ORGANIZED TISSUE  
IN VANDENBURG, HERMAN H., PROVIDENCE, RI, UNITED STATES  
VALENTINI, ROBERT F., CRANSTON, RI, UNITED STATES  
PI US 2002106627 A1 20020808  
AI US 1999-252324 A1 19990218 (9)  
PRAI US 1998-75054P 19980218 (60)  
US 1998-86370P 19980522 (60)  
DT Utility  
FS APPLICATION  
LREP DAVID S. RESNICK, NIXON-PEABODY, LLP, 101 FEDERAL STREET, BOSTON, MA, 02110-1832  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1416

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a method of screening a compound for bioactivity, comprising contacting a candidate bioactive compound with an organized tissue, and measuring in at least a cell of the organized tissue a biological parameter that is associated with bioactivity, wherein a change in the biological parameter that occurs as a result of the contacting step is indicative of bioactivity of the candidate compound.

L23 ANSWER 5 OF 26 USPATFULL

AN 2002:191193 USPATFULL

TI Peptide and polypeptide inhibitors of complement C1s

IN West, Robert R., Seattle, WA, UNITED STATES

Sheppard, Paul O., Granite Falls, WA, UNITED STATES

Fox, Brian A., Seattle, WA, UNITED STATES

PI US 2002102256 A1 20020801

AI US 2001-883727 A1 20010618 (9)

PRAI US 2000-212998P 20000621 (60)

DT Utility

FS APPLICATION

LREP Phillip B.C. Jones, J.D., Ph.D., ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA, 98102

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2867

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The complement system plays an important role in providing resistance to infections and in the pathogenesis of tissue injury. Yet an inappropriate activation of complement can result in a variety of disorders. The present invention provides C1s catalytic site-directed moieties, C1s exosite binding moieties, and bivalent polypeptide inhibitors comprising such moieties, which can be used to treat conditions characterized by inappropriate complement activation.

L23 ANSWER 6 OF 26 USPATFULL

AN 2002:133832 USPATFULL

TI USE OF NF-KB INHIBITION IN COMBINATION THERAPY FOR CANCER

IN BALDWIN, ALBERT S., CHAPEL HILL, NC, UNITED STATES

CUSACK, JAMES C., CHAPEL HILL, NC, UNITED STATES

MAYO, MARTY W., DURHAM, NC, UNITED STATES

WANG, GUN-YU, CHAPEL HILL, NC, UNITED STATES

PI US 2002068690 A1 20020606

AI US 1997-959160 A1 19971028 (8)

DT Utility

FS APPLICATION

LREP MYERS BIGEL SIBLEY & SAJOVEC, POST OFFICE BOX 37428, RALEIGH, NC, 27627

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN 5 Drawing Page(s)

LN.CNT 1000

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The use of NF-kappa B inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described.

L23 ANSWER 7 OF 26 USPATFULL

AN 2002:32544 USPATFULL

TI Tumor radiosensitization and/or chemopotentialization using isocoumarin derivatives

IN Reimer, Corinne L., Sommersville, MA, UNITED STATES

Agata, Naoki, Fujisawa, JAPAN

Takeuchi, Tomio, Tokyo, JAPAN

Kumagai, Hiroyuki, Chigasaki City, JAPAN  
Yoshioka, Takeo, Ayase-shi, JAPAN  
Ishizuka, Masaaki, Mishima City, JAPAN  
Kufe, Donald W., Wellesley, MA, UNITED STATES  
Weichselbaum, Ralph R., Chicago, IL, UNITED STATES

PI US 2002019366 A1 20020214  
AI US 2001-794417 A1 20010227 (9)  
PRAI US 2000-186071P 20000229 (60)

DT Utility  
FS APPLICATION

LREP Al A. Jecminek, Vice President, Licensing & Intellectual Property, Ilex  
Oncology Inc., 4545 Horizon Hill Blvd., San Antonio, TX, 78229

CLMN Number of Claims: 30

ECL Exemplary Claim: 1

DRWN 9 Drawing Page(s)

LN.CNT 1138

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for enhancing the efficacy of chemotherapy and/or radiation in  
the treatment of ~~cancer~~ in animals, particularly humans, is  
provided wherein certain isocoumarin derivatives which exhibit  
unique radiosensitization activity and/or chemopotential properties  
are employed in a combination treatment with ionizing radiation and/or  
chemotherapy.

L23 ANSWER 8 OF 26 USPATFULL

AN 2002:231092 USPATFULL

TI Steroid receptor modulator compounds and methods

IN Jones, Todd K., Solana Beach, CA, United States

Zhi, Lin, San Diego, CA, United States

Edwards, James P., San Diego, CA, United States

Tegley, Christopher M., San Diego, CA, United States

West, Sarah J., San Diego, CA, United States

PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S.  
corporation)

PI US 6448405 B1 20020910

AI US 1997-947428 19971008 (8)

RLI Division of Ser. No. US 1995-465429, filed on 5 Jun 1995, now patented,  
Pat. No. US 5696127 Continuation-in-part of Ser. No. US 1994-363529,  
filed on 22 Dec 1994, now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: Huang, Evelyn Mei

LREP Brobeck, Phleger & Harrison LLP

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 10950

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-steroidal compounds which are high affinity, high selectivity  
modulators for steroid receptors are disclosed. Also disclosed are  
pharmaceutical compositions incorporating such compounds, methods for  
employing the disclosed compounds and compositions for treating patients  
requiring steroid receptor agonist or antagonist therapy, intermediates  
useful in the preparation of the compounds and processes for the  
preparation of the steroid receptor modulator compounds.

L23 ANSWER 9 OF 26 USPATFULL

AN ~~2000:125226~~ USPATFULL

TI Intermediates for preparation of steroid receptor modulator compounds

IN Jones, Todd K., Solana Beach, CA, United States

Winn, David T., San Diego, CA, United States

Hamann, Lawrence G., San Diego, CA, United States

Zhi, Lin, San Diego, CA, United States

Farmer, Luc J., La Jolla, CA, United States

Davis, Robert L., Santee, CA, United States  
PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)  
PI US 6121450 20000919  
AI US 1997-947427 19971008 (8)  
RLI Division of Ser. No. US 1995-462643, filed on 5 Jun 1995, now patented, Pat. No. US 5696130 which is a continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Huang, Evelyn Mei  
LREP Elmer, J. Scott, Respess, William L.  
CLMN Number of Claims: 2  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 10966

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 10 OF 26 USPATFULL

AN 2000:95120 USPATFULL

TI Process for preparing steroid receptor modulator compounds

IN Jones, Todd K., Solana Beach, CA, United States  
Goldman, Mark E., San Diego, CA, United States  
Pooley, Charlotte L. F., San Diego, CA, United States  
Winn, David T., San Diego, CA, United States  
Edwards, James P., San Diego, CA, United States  
West, Sarah J., San Diego, CA, United States  
Tegley, Christopher M., San Diego, CA, United States  
Zhi, Lin, San Diego, CA, United States

PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)

PI US 6093821 20000725

AI US 1997-943853 19971008 (8)

RLI Division of Ser. No. US 1995-464541, filed on 5 Jun 1995, now patented, Pat. No. US 5688810 which is a continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Huang, Evelyn Mei

LREP Elmer, J. Scott, Respess, William L.

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 11155

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 11 OF 26 USPATFULL

AN 1999:155927 USPATFULL

TI Steroid receptor modulator compounds and methods

IN Jones, Todd K., Solana Beach, CA, United States



Tegley, Christopher M., San Diego, CA, United States

Zhi, Lin, San Diego, CA, United States

Edwards, James P., San Diego, CA, United States

PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)

PI US 5994544 19991130

AI US 1997-947413 19971008 (8)

RLI Division of Ser. No. US 1995-464360, filed on 5 Jun 1995, now patented, Pat. No. US 5693646 which is a continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Huang, Evelyn Mei

LREP Elmer, J. Scott, Respess, William L.

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 10956

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors and the method of preparing these compounds are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 12 OF 26 USPATFULL

AN 1999:151182 USPATFULL

TI Agents affecting thrombosis and hemostasis

IN Wolf, David L., Palo Alto, CA, United States

Sinha, Uma, San Francisco, CA, United States

PA COR Therapeutics Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 5990079 19991123

AI US 1998-16400 19980130 (9)

RLI Continuation of Ser. No. US 1995-469301, filed on 6 Jun 1995, now patented, Pat. No. US 5837679 which is a division of Ser. No. US 1994-268003, filed on 29 Jun 1994, now patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5597799 which is a continuation of Ser. No. US 1991-808329, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144

DT Utility

FS Granted

EXNAM Primary Examiner: Degen, Nancy

LREP Morgan, Lewis & Bockius LLP

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN 24 Drawing Figure(s); 15 Drawing Page(s)

LN.CNT 1981

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Analogues of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilia conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

L23 ANSWER 13 OF 26 USPATFULL

AN 1999:132526 USPATFULL

TI ATP-dependent protease and use of inhibitors for same in the treatment

of cachexia and muscle wasting  
IN Goldberg, Alfred L., Brookline, MA, United States  
PA The President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)  
PI US 5972636 19991026  
AI US 1997-982295 19971202 (8)  
RLI Division of Ser. No. US 1996-730310, filed on 11 Oct 1996, now patented, Pat. No. US 5786329 which is a division of Ser. No. US 1994-262497, filed on 20 Jun 1994, now patented, Pat. No. US 5565351 which is a division of Ser. No. US 1991-699184, filed on 13 May 1991, now patented, Pat. No. US 5340736  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Patterson, Jr., Charles L.  
LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)  
LN.CNT 2944

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The ATP-ubiquitin-dependent process has been shown to be responsible for the excessive protein degradation which occurs in conditions or disease states in which there is severe loss of body mass and negative nitrogen balance has been identified and key constituents in the process identified. A method of inhibiting the accelerated or enhanced proteolysis, a method of identifying inhibitors of the process, multipain and the proteasome inhibitor are the subject of the claimed invention.

L23 ANSWER 14 OF 26 USPATFULL

AN 1999:128513 USPATFULL  
TI Agents affecting thrombosis and hemostasis  
IN Wolf, David L., Palo Alto, CA, United States  
Sinha, Uma, San Francisco, CA, United States  
PA COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)  
PI US 5968897 19991019  
AI US 1998-16403 19980130 (9)  
RLI Continuation of Ser. No. US 1995-469301, filed on 6 Jun 1995, now patented, Pat. No. US 5837679 which is a division of Ser. No. US 1994-268003, filed on 29 Jun 1994, now patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5597799 which is a continuation of Ser. No. US 1991-808329, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144

DT Utility  
FS Granted  
EXNAM Primary Examiner: Degen, Nancy  
LREP Morgan, Lewis & Bockius LLP  
CLMN Number of Claims: 18  
ECL Exemplary Claim: 1  
DRWN 24 Drawing Figure(s); 15 Drawing Page(s)  
LN.CNT 1908

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB ~~Analog~~s of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

L23 ANSWER 15 OF 26 USPATFULL

AN 1998:144079 USPATFULL

TI Agents affecting thrombosis and hemostasis  
IN Wolf, David L., Palo Alto, CA, United States  
Sinha, Uma, San Francisco, CA, United States  
PA COR Therapeutics, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
PI US 5837679 19981117  
AI US 1995-469301 19950606 (8)  
RLI Division of Ser. No. US 1994-268003, filed on 29 Jun 1994, now patented,  
Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US  
1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5597799  
which is a continuation of Ser. No. US -808379 which is a  
continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990,  
now patented, Pat. No. US 5278144  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Fleisher, Mindy; Assistant Examiner: Degen, Nancy J.  
LREP Morrison & Foerster LLP  
CLMN Number of Claims: 46  
ECL Exemplary Claim: 1  
DRWN 23 Drawing Figure(s); 15 Drawing Page(s)  
LN.CNT 2092

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Analog of blood factors which are transiently inactive are useful in  
treatment of diseases characterized by thrombosis. In addition, modified  
forms of activated blood factors that generate the active blood factor  
in serum but have extended half-lives are useful in treating hemophilic  
conditions. These modified forms of the blood factor may be acylated  
forms which are slowly deacylated in vivo.

L23 ANSWER 16 OF 26 USPATFULL

AN 1998:88814 USPATFULL

TI ATP-dependent protease and use of inhibitors for same in the treatment  
of cachexia and muscle wasting

IN Goldberg, Alfred L., Brookline, MA, United States

PA The President and Fellows of Harvard College, Cambridge, MA, United  
States (U.S. corporation)

PI US 5786329 19980728

AI US 1996-730310 19961011 (8)

RLI Division of Ser. No. US 1994-262497, filed on 20 Jun 1994, now patented,  
Pat. No. US 5565351 which is a division of Ser. No. US 1991-699184,  
filed on 13 May 1991, now patented, Pat. No. US 5340736

DT Utility

FS Granted

EXNAM Primary Examiner: Patterson, Jr., Charles L.

LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.

CLMN Number of Claims: 3

ECL Exemplary Claim: 1

DRWN 23 Drawing Figure(s); 13 Drawing Page(s)

LN.CNT 2887

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The ATP-ubiquitin-dependent process has been shown to be responsible for  
the excessive protein degradation which occurs in conditions or disease  
states in which there is severe loss of body mass and negative nitrogen  
balance has been identified and key constituents in the process  
identified. A method of inhibiting the accelerated or enhanced  
proteolysis, a method of identifying inhibitors of the process,  
multipain and the proteasome inhibitor are the subject of the claimed  
invention.

L23 ANSWER 17 OF 26 USPATFULL

AN 97:115291-USPATFULL

TI Steroid receptor modulator compounds and methods

IN Jones, Todd K., Solana Beach, CA, United States  
Goldman, Mark E., San Diego, CA, United States

Pooley, Charlotte L.F., San Diego, CA, United States  
Winn, David T., San Diego, CA, United States  
Edwards, James P., San Diego, CA, United States  
West, Sarah J., San Diego, CA, United States  
Tegley, Christopher M., San Diego, CA, United States  
Zhi, Lin, San Diego, CA, United States  
Hamann, Lawrence G., San Diego, CA, United States  
Farmer, Luc J., La Jolla, CA, United States  
Davis, Robert L., Santee, CA, United States

PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)

PI US 5696133 19971209

AI US 1995-465556 19950605 (8)

RLI Continuation-in-part of Ser. No. US 1994-363529, filed on 23 Dec 1994, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Huang, Evelyn

LREP Jurgensen, Thomas E., Respess, William L., Elmer, James Scott

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 11054

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 18 OF 26 USPATFULL

AN 97:115288 USPATFULL

TI Tricyclic steroid receptor modulator compounds and methods

IN Jones, Todd K., Solana Beach, CA, United States

Winn, David T., San Diego, CA, United States

Goldman, Mark E., San Diego, CA, United States

Hamann, Lawrence G., San Diego, CA, United States

Zhi, Lin, San Diego, CA, United States

Farmer, Luc J., La Jolla, CA, United States

Davis, Robert L., Santee, CA, United States

PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)

PI US 5696130 19971209

AI US 1995-462643 19950605 (8)

RLI Continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Huang, Evelyn

LREP Jurgensen, Thomas E., Respess, William L., Elmer, James Scott

CLMN Number of Claims: 35

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 11334

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for ~~employing the disclosed compounds and compositions for treating patients~~ requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 19 OF 26 USPATFULL

AN 97:115285 USPATFULL

TI Steroid receptor modulator compounds and methods

IN Jones, Todd K., Solana Beach, CA, United States

Zhi, Lin, San Diego, CA, United States

Edwards, James P., San Diego, CA, United States

Tegley, Christopher M., San Diego, CA, United States

West, Sarah J., San Diego, CA, United States

PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)

PI US 5696127 19971209

AI US 1995-465429 19950605 (8)

RLI Continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Huang, Evelyn

LREP Jurgensen, Thomas E., Respass, William L., Elmer, James Scott

CLMN Number of Claims: 36

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 11518

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 20 OF 26 USPATFULL

AN 97:112477 USPATFULL

TI Steroid receptor modulator compounds and methods

IN Jones, Todd K., Solana Beach, CA, United States

Zhi, Lin, San Diego, CA, United States

Tegley, Christopher M., San Diego, CA, United States

Winn, David T., San Diego, CA, United States

Hamann, Lawrence G., San Diego, CA, United States

Edwards, James P., San Diego, CA, United States

West, Sarah J., San Diego, CA, United States

PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)

PI US 5693647 19971202

AI US 1995-464546 19950605 (8)

RLI Continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Huang, Evelyn

LREP Jurgensen, Thomas E., Respass, William L., Elmer, James Scott

CLMN Number of Claims: 27

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 11185

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 21 OF 26 USPATFULL  
AN 97:112476 USPATFULL  
TI Steroid receptor modulator compounds and methods  
IN Jones, Todd K., Solana Beach, CA, United States  
Tegley, Christopher M., San Diego, CA, United States  
Zhi, Lin, San Diego, CA, United States  
Edwards, James P., San Diego, CA, United States  
West, Sarah J., San Diego, CA, United States  
PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S.  
corporation)  
PI US 5693646 19971202  
AI US 1995-464360 19950605 (8)  
RLI Continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994,  
now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Huang, Evelyn  
LREP Jurgensen, Thomas E., Respass, William L., Elmer, James Scott  
CLMN Number of Claims: 28  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 11285

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-steroidal compounds which are high affinity, high selectivity  
modulators for steroid receptors are disclosed. Also disclosed are  
pharmaceutical compositions incorporating such compounds, methods for  
employing the disclosed compounds and compositions for treating patients  
requiring steroid receptor agonist or antagonist therapy, intermediates  
useful in the preparation of the compounds and processes for the  
preparation of the steroid receptor modulator compounds.

L23 ANSWER 22 OF 26 USPATFULL  
AN 97:107096 USPATFULL  
TI Steroid receptor modulator compounds and methods  
IN Jones, Todd K., Solana Beach, CA, United States  
Goldman, Mark E., San Diego, CA, United States  
Pooley, Charlotte L.F., San Diego, CA, United States  
Winn, David T., San Diego, CA, United States  
Edwards, James P., San Diego, CA, United States  
West, Sarah J., San Diego, CA, United States  
Tegley, Christopher M., San Diego, CA, United States  
Zhi, Lin, San Diego, CA, United States  
PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S.  
corporation)  
PI US 5688810 19971118  
AI US 1995-464541 19950605 (8)  
RLI Continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994,  
now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Huang, Evelyn  
LREP Jurgensen, Thomas E., Respass, William L., Elmer, James Scott  
CLMN Number of Claims: 27  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 11318

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-steroidal compounds which are high affinity, high selectivity  
modulators for steroid receptors are disclosed. Also disclosed are  
pharmaceutical compositions incorporating such compounds, methods for  
employing the disclosed compounds and compositions for treating patients  
requiring steroid receptor agonist or antagonist therapy, intermediates  
useful in the preparation of the compounds and processes for the

preparation of the steroid receptor modulator compounds.

L23 ANSWER 23 OF 26 USPATFULL

AN 97:107094 USPATFULL

TI Steroid receptor modulator compounds and methods

IN Jones, Todd K., Solana Beach, CA, United States

Winn, David T., San Diego, CA, United States

Zhi, Lin, San Diego, CA, United States

Hamann, Lawrence G., San Diego, CA, United States

Tegley, Christopher M., San Diego, CA, United States

Pooley, Charlotte L. F., San Diego, CA, United States

PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)

PI US 5688808 19971118

AI US 1995-463231 19950605 (8)

RLI Continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Huang, Evelyn

LREP Jurgensen, Thomas E., Respass, William L., Elmer, James Scott

CLMN Number of Claims: 27

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 11240

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 24 OF 26 USPATFULL

AN 97:3818 USPATFULL

TI Heterocyclic anthracycline analogs

IN Attardo, Giorgio, Laval, Canada

Kraus, Jean-Louis, Marseilles, France

Courchesne, Marc, Laval-des-Rapides, Canada

Lamonthé, Serge, Boisbriand, Canada

Lavallée, Jean-François, Laval, Canada

Lebeau, Elaine, Kamloops, Canada

Nguyen, Dieu, Chomedey, Canada

Rej, Rabindra, Montreal, Canada

St-Denis, Yves, Montreal, Canada

Wang, Wuyi, St-Laurent, Canada

Xu, Yao-Chang, Indianapolis, IN, United States

Barbeau, France, Ste-Thérèse, Canada

Belleau, deceased, Bernard, late of Westmount, Canada by Pierette

Belleau, executrix

PA Biochem-Pharma Inc., Laval, Canada (non-U.S. corporation)

PI US 5593970 19970114

AI US 1994-263925 19940620 (8)

RLI Continuation-in-part of Ser. No. US 1993-2766, filed on 13 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-859244, filed on 26 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-536107, filed on 11 Jun 1990, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Peselev, Elli

LREP Nixon & Vanderhye

CLMN Number of Claims: 34

ECL Exemplary Claim: 1,32

DRWN No Drawings

LN.CNT 10624

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel pyrano heterocyclic anthracycline derivatives are described, which are useful in the treatment of cancer and tumors, such as breast cancer, leukemia, lung cancer, colon cancer, ovarian cancer, renal cancer, and melanoma. As well, these compounds may be used ex vivo for the treatment of cancerous bone marrow before retransplanting said marrow in a patient. Pharmaceutical compositions and methods of preparing the compounds are also described.

L23 ANSWER 25 OF 26 USPATFULL

AN 96:94482 USPATFULL

TI ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting

IN Goldberg, Alfred L., Brookline, MA, United States

PA The President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

PI US 5565351 19961015

AI US 1994-262497 19940620 (8)

RLI Division of Ser. No. US 1991-699184, filed on 13 May 1991, now patented, Pat. No. US 5340736

DT Utility

FS Granted

EXNAM Primary Examiner: Patterson, Jr., Charles L.

LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN 23 Drawing Figure(s); 13 Drawing Page(s)

LN.CNT 2875

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The ATP-ubiquitin-dependent process has been shown to be responsible for the excessive protein degradation which occurs in conditions or disease states in which there is severe loss of body mass and negative nitrogen balance has been identified and key constituents in the process identified. A method of inhibiting the accelerated or enhanced proteolysis, a method of identifying inhibitors of the process, multipain and the proteasome inhibitor are the subject of the claimed invention.

L23 ANSWER 26 OF 26 USPATFULL

AN 94:73223 USPATFULL

TI ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting

IN Goldberg, Alfred L., Brookline, MA, United States

PA The President & Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

PI US 5340736 19940823

AI US 1991-699184 19910513 (7)

DT Utility

FS Granted

EXNAM Primary Examiner: Patterson, Jr., Charles L.

LREP Sterne, Kessler, Goldstein & Fox

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN 12 Drawing Figure(s); 12 Drawing Page(s)

LN.CNT 2720

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The ATP-ubiquitin-dependent process has been shown to be responsible for the excessive protein degradation which occurs in conditions or disease states in which there is severe loss of body mass and negative nitrogen balance has been identified and key constituents in the process identified. A method of inhibiting the accelerated or enhanced



proteolysis, a method of identifying inhibitors of the process,  
multipain and the proteasome inhibitor are the subject of the claimed  
invention.

=> d his

(FILE 'HOME' ENTERED AT 15:52:19 ON 03 MAY 2003)

FILE 'REGISTRY' ENTERED AT 15:59:20 ON 03 MAY 2003

L1               STRUCTURE UPLOADED  
L2               0 S L1 FULL  
L3               0 S L1 SSS  
L4               0 S L1  
L5               0 S L1 SSS FUL  
L6               0 S L1

FILE 'CAPLUS, USPATFULL, BIOSIS, MEDLINE, CANCERLIT, DRUGU' ENTERED AT  
16:06:42 ON 03 MAY 2003

L7               1917 S ISOCOUMARIN#####  
L8               133145 S GLUCOCORTICOID####  
L9               227511 S DEXAMETHASON### OR PREDNISON###  
L10              26 S L7 AND L8  
L11              17 S L7 AND L9  
L12              28 S L10 OR L11  
L13              143 S L7 AND CANCER####  
L14              17 S L13 AND L9  
L15              25 S L13 AND L8  
L16              27 S L14 OR L15  
L17              86336 S VINCRISTIN##  
L18              117909 S DOXORUBICIN##  
L19              128154 S CISPLATIN  
L20              156136 S CYCLOPHOSPHAMID##  
L21              360550 S L20 OR L19 OR L18 OR L17  
L22              15 S L21 AND L7  
L23              26 DUP REMOVE L16 (1 DUPLICATE REMOVED)

=> dup remove l22

PROCESSING COMPLETED FOR L22

L24              11 DUP REMOVE L22 (4 DUPLICATES REMOVED)

=> s l23 or l24

L25              34 L23 OR L24

=> d l24 1-11 bib,ab

L24   ANSWER 1 OF 11   CAPLUS   COPYRIGHT 2003 ACS               DUPLICATE 1  
AN    2002:850322   CAPLUS  
DN    137:333136  
TI    Tumor chemopotential using isocoumarin derivatives  
IN    Agata, Naoki; Kharbanda, Surender  
PA    USA  
SO    U.S. Pat. Appl. Publ., 30 pp., Cont.-in-part of U. S. Ser. No. 794,417.  
      CODEN: USXXCO  
DT    Patent  
LA    English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002165210	A1	20021107	US 2002-82521	20020223
	US 2002019366	A1	20020214	US 2001-794417	20010227
PRAI	US 2000-186071P	P	20000229		
	US 2001-794417	A2	20010227		
AB	A method for enhancing the efficacy of chemotherapy in the treatment of				

cancer in animals, particularly humans, is provided wherein **isocoumarin** derivs. that exhibit unique chemopotential properties are employed in a combination treatment with chemotherapy. NM-3 [2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid] showed antiangiogenic activity and enhanced dexamethasone-induced apoptosis in human multiple myeloma cells.

L24 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 2  
AN 2002:123594 CAPLUS  
DN 136:161349  
TI Tumor radiosensitization and/or chemopotential using  
**isocoumarin** derivatives  
IN Reimer, Corinne L.; Agata, Naoki; Takeuchi, Tomio; Kumagai, Hiroyuki;  
Yoshioka, Takeo; Ishizuka, Masaaki; Kufe, Donald W.; Weichselbaum, Ralph  
R.  
PA USA  
SO U.S. Pat. Appl. Publ., 22 pp.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002019366	A1	20020214	US 2001-794417	20010227
	WO 2002072123	A1	20020919	WO 2001-US7965	20010313
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002165210	A1	20021107	US 2002-82521	20020223
PRAI	US 2000-186071P	P	20000229		
	US 2001-794417	A	20010227		

OS MARPAT 136:161349  
AB A method for enhancing the efficacy of chemotherapy and/or radiation in the treatment of cancer in animals, particularly humans, is provided wherein certain **isocoumarin** derivs. which exhibit unique radiosensitization activity and/or chemopotential properties are employed in a combination treatment with ionizing radiation and/or chemotherapy. Colon 26 adenocarcinoma cells transplanted in mice were inhibited with combination therapy of **cyclophosphamide** and 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid.

L24 ANSWER 3 OF 11 USPATFULL  
AN 2002:133832 USPATFULL  
TI ~~USE OF NF-KB INHIBITION~~ IN COMBINATION THERAPY FOR CANCER  
IN BALDWIN, ALBERT S., CHAPEL HILL, NC, UNITED STATES  
CUSACK, JAMES C., CHAPEL HILL, NC, UNITED STATES  
MAYO, MARTY W., DURHAM, NC, UNITED STATES  
WANG, CUN-YU, CHAPEL HILL, NC, UNITED STATES  
PI US 2002068690 A1 20020606  
AI US 1997-959160 A1 19971028 (8)  
DT Utility  
FS APPLICATION  
LREP MYERS BIGEL SIBLEY & SAJOVEC, POST OFFICE BOX 37428, RALEIGH, NC, 27627  
CLMN Number of Claims: 13  
ECL Exemplary-Claim: -1  
DRWN 5 Drawing Page(s)  
LN.CNT 1000  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The use of NF- $\kappa$ B inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described.

L24 ANSWER 4 OF 11 USPATFULL

AN 2002:239051 USPATFULL

TI **Isocoumarin** derivatives inhibiting angiogenesis

IN Lee, Jung Joon, Taejon-si, KOREA, REPUBLIC OF

Kim, Hang-Sub, Taejon-si, KOREA, REPUBLIC OF

Lee, Jeong-Hyung, Taejon-si, KOREA, REPUBLIC OF

Hong, Young-Soo, Taejon-si, KOREA, REPUBLIC OF

Park, Yun Joo, Taejon-si, KOREA, REPUBLIC OF

PA Korea Research Institute of Bioscience and Biotechnology, KOREA, REPUBLIC OF (non-U.S. corporation)

PI US 6451846 B1 20020917

WO 2000075124 20001214

AI US 2002-980904 20020226 (9)

WO 2000-KR576 20000601

20020226 - PCT-371 date

PRAI KR 1999-20374 19990603

DT Utility

FS GRANTED

EXNAM Primary Examiner: Owens, Amelia

LREP Roberts & Mercanti, LLP

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 490

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel **isocoumarin** derivatives inhibiting angiogenesis, a method for preparation thereof and pharmaceutical compositions comprising the said derivatives as pharmaceutically active ingredients. More particularly, the present invention relates to novel **isocoumarin** derivatives represented by formula (1), especially 6,8-dihydroxy-4-acetyl-**isocoumarin**, a method for preparing 6,8-dihydroxy-4-acetyl-**isocoumarin** from fungi, and pharmaceutical compositions comprising the compounds and/or 6,8-dihydroxy-4-acetyl-**isocoumarin** as pharmaceutically active ingredients, which would be effective for the treatment of angiogenic diseases such as cancers, rheumatoid arthritis and diabetic retinopathy.

L24 ANSWER 5 OF 11 USPATFULL

AN 2002:39931 USPATFULL

TI Camptothecin derivatives

IN Yang, Li-Xi, San Francisco, CA, United States

Pan, Xiandao, San Francisco, CA, United States

Wang, Huijuan, San Francisco, CA, United States

PA California Pacific Medical Center, San Francisco, CA, United States (U.S. corporation)

PI US 6350756 B1 20020226

AI US 2001-797769 20010301 (9)

PRAI US 2001-263040P 20010118 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Dentz, Bernard

LREP Cooley Godward LLP

CLMN Number of Claims: 54

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 3407

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB (20S) esters of camptothecin analogs are provided. The compounds are (20S) esters of an oxyalkanoic acid and camptothecin, which is optionally substituted at the 7, 9, 10, 11, and 12 positions of the

camptothecin ring. The compounds are useful for treating cancer.

L24 ANSWER 6 OF 11 MEDLINE DUPLICATE 3  
AN 2002099665 MEDLINE  
DN 21818588 PubMed ID: 11830534  
TI Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3,  
an inhibitor of angiogenesis.  
AU Reimer Corinne L; Agata Naoki; Tammam Jennifer G; Bamberg Michael;  
Dickerson William M; Kamphaus George D; Rook Susan L; Milhollen Michael;  
Fram Robert; Kalluri Raghu; Kufe Donald; Kharbanda Surender  
CS ILEX Oncology, Inc., 20 Overland Street, Boston, MA 02215, USA.  
SO CANCER RESEARCH, (2002 Feb 1) 62 (3) 789-95.  
Journal code: 2984705R. ISSN: 0008-5472.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200203  
ED Entered STN: 20020207

Last Updated on STN: 20020307

Entered Medline: 20020305

AB Antiangiogenic therapy, although effective in shrinking tumors, has not yet been established as a standalone treatment for cancer. This therapeutic limitation can be overcome by combining angiogenesis inhibitors with chemotherapeutic agents. NM-3, a small molecule **isocoumarin**, is a recently discovered angiogenesis inhibitor. Here we demonstrate that NM-3 inhibits the proliferation of human umbilical vein endothelial cells in vitro, at concentrations 10-fold less than those required to inhibit normal fibroblasts or tumor cells (HT29, MKN28, and MCF-7). NM-3 alone inhibits endothelial sprouting and tube formation in vitro. The results also show that synergistic antiproliferative activity is observed when human umbilical vein endothelial cells are treated with NM-3 in combination with 5-fluorouracil. The effects of treatment with NM-3 and various chemotherapeutic agents were also evaluated in tumor xenografts. The results demonstrate that combined treatment with NM-3 and chemotherapeutic agents significantly reduced mean tumor volume compared with either treatment alone, with no effects on body weight changes. Taken together, these findings demonstrate that NM-3 is a well-tolerated angiogenesis inhibitor that significantly increases the efficacy of existing antineoplastic agents.

L24 ANSWER 7 OF 11 MEDLINE DUPLICATE 4  
AN 2002193206 MEDLINE  
DN 21923488 PubMed ID: 11926548  
TI In vitro cytotoxicity of some natural and semi-synthetic **isocoumarins** from *Paepalanthus bromelioides*.  
AU Devienne Karina F; Raddi MariaStellaG; Varanda Eliana A; Vilegas Wagner  
CS Instituto de Quimica de Araraquara, SP, Brazil.  
SO ZEITSCHRIFT FUR NATURFORSCHUNG. SECTION C. JOURNAL OF BIOSCIENCES, (2002 Jan-Feb) 57 (1-2) 85-8.  
Journal code: 8912155. ISSN: 0341-0382.  
CY Germany; Germany, Federal Republic of  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200205  
ED Entered STN: 20020404

Last Updated on STN: 20020511

Entered Medline: 20020510

AB Numerous natural compounds have a potential for therapeutic applications, but may have to be chemically modified to alter toxic side effects. We investigated structural parameters that could affect the cytotoxicity of **isocoumarins** similar to 9,10-dihydroxy-5,7-dimethoxy-1H-

naphtho(2,3c)pyran-1-one (paepalantine 1). Paepalantine 1 has antimicrobial activity, as well as significant in vitro cytotoxic effects in the McCoy cell line. Two other natural and two semi-synthetic **isocoumarins** with similar structures obtained from the capitula of Paepalanthus bromelioides were tested on the same cell line by the neutral red assay. Substitution of the 9 and/or 10-OH group made these compounds less cytotoxic.

L24 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2003 ACS

AN 2000:351401 CAPLUS

DN 133:12742

TI A method of ~~genetic vector~~ delivery using immunosuppression and a blood-organ barrier modifier

IN Chiocca, E. Antonio; Ikeda, Keiro; Bartus, Raymond T.

PA The General Hospital Corporation, USA; Alkermes, Inc.

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000029033	A2	20000525	WO 1999-US27206	19991117
	WO 2000029033	A3	20001005		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-108881P P 19981117

AB A method is provided for administering a ~~genetic vector~~ to a target cell in a patient by immunosuppressing the patient and ~~administering~~ the genetic vector. Also provided is a method of administering a genetic vector to a target cell in a patient by administering a complement inhibitor and the genetic vector. The invention also relates to further administering a blood-organ barrier modifier.

L24 ANSWER 9 OF 11 DRUGU COPYRIGHT 2003 THOMSON DERWENT

AN 2001-04905 DRUGU P

TI NM3, an orally bioavailable small molecule inhibitor of VEGF expression inhibits xenograft tumor growth alone and enhances antitumor effects of standard chemotherapy.

AU Reimer C L; ~~Rook C L~~; Dickerson M; Bamberg M; Rice G

CS Ilex-Oncology

LO Boston, Mass., USA

SO Clin.Cancer Res. (6, Suppl., 4520S, 2000)

CODEN: CCREF

ISSN: 1078-0432

AV ILEX Oncology, Inc. Boston, MA 02215, U.S.A.

LA English

DT Journal

FA AB; LA; CT

FS Literature

AB The antitumor activity of i.p. NM3, a small molecule **isocoumarin** that ~~specifically inhibits VEGF expression~~ at the mRNA and protein levels, alone and in combination with **cyclophosphamide** (CY), **carboplatin** (CB) and **5-fluorouracil** (5-FU) was investigated in 2 different mouse xenograft tumor models. NM3 itself inhibited tumor growth and enhanced the responses to CY, CB and 5-FU. The findings support the use of NM3 in planned Phase I clinical trials alone and in combination with chemotherapy in patients with solid tumors. Its p.o.

bioavailability should confer greater dosing convenience than monoclonal antibody therapy and its 6-8 hr half-life should confer a greater safety profile than the prolonged half lives of anti-VEGF or anti-KDR antibodies. (conference abstract: 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, 2000).

L24 ANSWER 10 OF 11 USPATFULL

AN 97:7935 USPATFULL

TI 6-[X-(2-hydroxyethyl) aminoalkyl]-5,11-dioxo-5,6-dihydro-11-H-indeno[1,2-c]isoquinolines and their use as antineoplastic agents

IN Michalsky, deceased, Jiri, late of Olomouc, Czechoslovakia by Miluska

Michalska, Jana Michalska, legal heirs

Hrbata, Jiri, Olsany, Czechoslovakia

Krepelka, Jiri, Praha, Czechoslovakia

Melka, Milan, Hradec Kralove, Czechoslovakia

Miko, Milan, Bratislava, Czechoslovakia

Hruby, Milan, Olomouc, Czechoslovakia

Ferenc, Milan, Olomouc, Czechoslovakia

Skacelova, Eva, Hnevotin, Czechoslovakia

Kejhova, Irena, Praha, Czechoslovakia

Reichlova, Rzena, Praha, Czechoslovakia

Kargerova, Anna, Praha, Czechoslovakia

Sediva, Jitka, Praha, Czechoslovakia

Kolonicky, Alois, Pardubice, Czechoslovakia

Urbanec, Josef, Hradec Kraalove, Czechoslovakia

PA VUB a.s, Praha, Czechoslovakia (non-U.S. corporation)

PI US 5597831 19970128

AI US ~~5595~~ 533859 19950926 (8)

RLI Continuation of Ser. No. US 1994-199153, filed on 13 Jul 1994, now abandoned

PRAI CS 1991-2669 19910829

DT Utility

FS Granted

EXNAM Primary Examiner: Rotman, Alan L.

LREP Burns, Doane, Swecker & Mathis, L.L.P.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 490

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 11 OF 11 USPATFULL

AN 97:3818 USPATFULL

TI Heterocyclic anthracycline analogs

IN Attardo, Giorgio, Laval, Canada

Kraus, Jean-Louis, Marseilles, France

Courchesne, Marc, Laval-des-Rapides, Canada

Lamonthe, Serge, Boisbriand, Canada

Lavall ee, Jean-Fran.cedilla.ois, Laval, Canada

Lebeau, Elaine, Kamloops, Canada

Nguyen, Dieu, Chomedey, Canada

Rej, Rabindra, Montreal, Canada

St-Denis, Yves, Montreal, Canada

Wang, Wuyi, St-Laurent, Canada

Xu, Yao-Chang, Indianapolis, IN, United States

Barbeau, France, Ste-Th er ese, Canada

Belleau, deceased, Bernard, late of Westmount, Canada by Pierette

Belleau, executrix

PA Biochem Pharma Inc., Laval, Canada (non-U.S. corporation)

PI US 5593970 19970114

AI US ~~1994~~ 263925 19940620 -(8)

RLI Continuation-in-part of Ser. No. US 1993-2766, filed on 13 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-859244, filed on 26 Mar 1992, now abandoned which is a continuation-in-part of

Ser. No. US 1990-536107, filed on 11 Jun 1990, now abandoned

DT Utility  
FS Granted  
EXNAM Primary Examiner: Peselev, Elli  
LREP Nixon & Vanderhye  
CLMN Number of Claims: 34  
ECL Exemplary Claim: 1,32  
DRWN No Drawings  
LN.CNT 10624

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel pyrano heterocyclic anthracycline derivatives are described, which are useful in the treatment of cancer and tumors, such as breast cancer, leukemia, lung cancer, colon cancer, ovarian cancer, renal cancer, and melanoma. As well, these compounds may be used ex vivo for the treatment of cancerous bone marrow before retransplanting said marrow in a patient. Pharmaceutical compositions and methods of preparing the compounds are also described.

---

---